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Introduction
Genetic studies and clinical observations suggest that the insulin-
like growth factor (IGF) signaling pathway has a fundamental role
in regulating animal growth and development, as well as in
maintaining adult homeostasis (Clemmons, 2007; Duan and Xu,
2005; Firth and Baxter, 2002). Most, if not all, IGFs in extracellular
fluid are present in complexes with specific, high-affinity IGF
binding proteins (IGFBPs). In the bloodstream, the majority of
circulating IGFs are in a ternary complex with IGFBP3 and a
protein termed acid-labile subunit (ALS) (Firth and Baxter, 2002;
Yamada and Lee, 2009). This ternary complex not only serves as
a reservoir for IGF release, but also greatly increases the half-life
of IGFs. In addition, the IGF–IGFBP complexes in the circulation
and in tissues help to prevent potential cross binding of IGFs to the
insulin receptor. Therefore, IGFBP3 functions as a carrier protein
and regulates circulating IGF turnover, transport, and distribution.
IGFBP3 is a member of the IGFBP gene family. Similarly to
other IGFBPs, IGFBP3 is comprised of three recognizable domains
of similar size (~80 residues): an N-terminal domain, typically
with 12 conserved cysteine residues, a C-terminal domain with six
conserved cysteine residues, and a central L-domain that is thought
to act as a hinge between the N- and C-domains (Firth and Baxter,
2002; Yamada and Lee, 2009). The N- and C-domains are required
for high-affinity ligand binding and are highly conserved across
species (Duan and Xu, 2005). In addition to its role as the major
IGF carrier protein in the circulation, IGFBP3 has also been shown
to inhibit and/or potentiate the actions of IGF in a wide variety of
cultured human and rodent cells. Furthermore, IGFBP3 has been
shown to possess distinct biological effects independently of IGF
(Firth and Baxter, 2002; Jogie-Brahim et al., 2009; Yamada and
Lee, 2009). There is general agreement that the IGF–IGF-1R-
independent actions of IGFBP3 might contribute to the
pathophysiology of a number of human diseases, including cancer
and diabetes, although the actual role of IGFBP3 is still unclear
(Firth and Baxter, 2002; Jogie-Brahim et al., 2009; Yamada and
Lee, 2009). Recent studies have implicated the interaction of
IGFBP3 with a variety of proteins or signaling cascades that are
crucial to cell proliferation and/or apoptosis (Firth and Baxter,
2002; Jogie-Brahim et al., 2009; Yamada and Lee, 2009).
Despite these advances, many important questions remain.
IGFBP3 has been shown to exhibit ligand-dependent, as well as
ligand-independent, actions in cultured mammalian cells. However,
its in vivo modes of action and the underlying mechanisms are
poorly understood. Mammalian IGFBP3 has a functional NLS and
can be found in the nucleus of cultured tumor cells (Firth and
Baxter, 2002; Jogie-Brahim et al., 2009), but the functional
significance of this NLS in mediating the ligand-independent
actions of IGFBP3 is also unclear and whether the NLS of IGFBP3
has a role in vivo is unknown. Likewise, the mammalian IGFBP3
N-domain contains a functional transactivation domain (Zhao et
al., 2006). It is not clear whether this activity is conserved or
whether it has any biological significance in vivo.
Most research on the developmental role of IGFs and IGFBPs
has relied on rodent models, and attempts to elucidate the molecular
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and cellular basis of IGFBP have been hampered by the
inaccessibility of the mammalian fetus enclosed in the uterus and
the greater redundancy of mammalian systems. We have shown
that zebrafish Igfbp3 has an important role in the formation and
differentiation of the pharyngeal skeleton and inner ear (Li et al.,
2005). The objectives of this study were to determine: (1) whether
the IGF binding domain (IBD), nuclear localization signal (NLS),
and transactivation domain (TA) are conserved in zebrafish Igfbp3;
(2) whether Igfbp3 can use any of these domains to exert ligand-
dependent and/or ligand-independent actions in an in vivo setting;
and (3) the molecular mechanisms underlying its IGF-independent
actions.
Results
The NLS, IBD and TA domains are conserved and
functional in zebrafish Igfbp3
Human IGFBP3 binds IGFs primarily using its high-affinity binding
site located in the N-domain, although its C-domain also has a role
(Buckway et al., 2001; Hong et al., 2002; Imai et al., 2000).
According to Imai and colleagues (Imai et al., 2000), R69, P70,
L71, L74 and L75 are particularly crucial for its IGF binding.
Sequence analysis indicates that these residues are all conserved in
zebrafish Igfbp3 (Fig. 1A). To ascertain that zebrafish Igfbp3 is a
functional IGFBP, we constructed an expression plasmid by
subcloning the zebrafish Igfbp3 ORF into the pCS2+EGFP plasmid.
A human IGFBP5 pCS2+EGFP plasmid was used as a positive
control. After these mutants were introduced into HEK293T cells
by transient transfection, conditioned medium was prepared and
analyzed. Western immunoblotting results showed the successful
expression and secretion of Igfbp3–EGFP and IGFBP5–EGFP
fusion proteins (Fig. 1B, left panel). Unexpectedly, ligand blotting
analysis showed that human IGFBP5–EGFP but not zebrafish
Igfbp3–EGFP was capable of IGF binding (Fig. 1B, right panel).
We speculated that tagging of EGFP to the zebrafish Igfbp3 might
disrupt its ligand-binding property. To test this idea, we constructed
a new expression plasmid by subcloning the zebrafish Igfbp3 ORF
into the pCS2+ vector. When the plasmid was introduced in
HEK293T cells, a novel IGFBP of approximately 45 kDa was
detected in the conditioned medium (Fig. 1B, right), suggesting
that the zebrafish Igfbp3 ORF indeed encodes a functional IGFBP.
Zebrafish Igfbp3 was able to bind both IGF-1 and IGF-2 (Fig. 1C).
To determine whether the conserved IGF binding domain (IBD) in
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Fig. 1. The IGF binding domain (IBD) and transactivation (TA) domain
are conserved and functional in zebrafish Igfbp3. (A)Sequence alignment
of the N-domain of human IGFBP5, IGFBP3, IGFBP1 and zebrafish Igfbp3.
Open boxes indicate residues known to be crucial for IGF binding in human
IGFBP5 and IGFBP3. # marks the five residues altered by site-directed
mutagenesis in the IBD mutant. Asterisks indicate residues known to be
important for the TA activity in human IGFBP5, and the four residues altered
by site-directed mutagenesis in the TA dead mutant are indicated by carets.
(B)Western immunoblotting (left) and ligand blotting (right) analysis of
human IGFBP5–EGFP (BP5-EGFP), zebrafish Igfbp3–EGFP (BP3-EGFP)
and zebrafish Igfbp3 (BP3) using anti-GFP antibody and DIG-labeled human
IGF-1, respectively. Asterisks denote endogenous IGFBPs, serving as internal
controls. (C)Ligand-blotting analysis of culture medium conditioned by
HEK293T cells transfected with zebrafish Igfbp3 (BP3), its IBD, NLS,
IBD+NLS (I+N), TA dead (TA) mutant or empty vector (Mock). Arrows
denote zebrafish Igfbp3 and its mutant proteins. Asterisks denote the
endogenous IGFBPs, serving as internal controls. Upper panel shows results
using DIG-labeled human IGF-1 and lower panel using DIG-labeled human
IGF-2. (D)Zebrafish Igfbp3 N-domain has transactivation activity. The N-
domain of zebrafish Igfbp3 (BP3N) and human IGFBP1 (BP1N) were fused to
Gal4 DNA-binding domain and transfected into HEK293T cells together with
a Gal4 reporter plasmid. The transactivation activity is expressed as fold
increase over the pBind control group. Values are expressed as means ± s.d.,
n3. Groups with different letters are significantly different from each other
(P<0.05). The expression levels of these fusion proteins were analyzed by
western immunoblotting using an anti-GAL4 antibody and shown in the right
panel. (E)The TA-dead mutant (BP3N-TA) has no transactivation activity.
Values are expressed as fold increase over the pBind control group. Values are
means ± s.d., n3. Groups with different letters are significantly different from
each other (P<0.05). The expression levels of these mutant fusion proteins are











zebrafish Igfbp3 is responsible for its IGF binding, and to generate
an IBD mutant for subsequent in vivo functional analysis, we
generated a zebrafish Igfbp3 IBD mutant by changing K70, P71,
L72, L75, and L76 of zebrafish Igfbp3 to N70, Q71, Q72, Q75 and
Q76, respectively. As shown in Fig. 1C, this mutant did not bind
to IGF-1 or IGF-2.
Previous studies suggest that mammalian IGFBP3 is not only
secreted but is also present in the nucleus (Firth and Baxter, 2002),
and its N-domain has transactivation activity (Xu et al., 2004;
Zhao et al., 2006). To determine whether this activity is conserved,
the zebrafish Igfbp3 N-domain (amino acids 1–81) was fused to
the Gal4 DNA-binding domain (Gal4DBD), and the activity was
measured. As shown in Fig. 1D, the zebrafish Igfbp3 N-domain
caused a 12.18±2.53-fold increase in GAL4-dependent
transactivation (n3, P<0.001). In comparison, the IGFBP-1 N-
domain had no significant activity. Western immunoblot analysis
revealed that expression levels of these fusion proteins were similar
(Fig. 1D). We next compared the sequence of the zebrafish Igfbp3
N-domain with that of human IGFBP5 N-domain, whose
transactivation domain (TA) has been extensively characterized
(Xu et al., 2004; Zhao et al., 2006). Among the eight residues in
the human IGFBP5 N-domain that are known to be crucial for its
transactivation ability (Zhao et al., 2006), six (E8, D11, D12, E31,
P32 and E44) are conserved in zebrafish Igfbp3 (Fig. 1A).
Importantly, these six residues are not conserved in human IGFBP-
1, which has no transactivation activity (Xu et al., 2004) (also see
Fig. 1D). We generated a TA-dead mutant for subsequent functional
analyses by mutating E8, D11, D12 and E44 of zebrafish Igfbp3
into the corresponding residues in human IGFBP1 (E8A, D11S,
D12A, E44L). As shown in Fig. 1E, the TA-dead mutant (BP3N-
TA) had essentially no transactivation activity. The expression
levels of the fusion protein were similar (Fig. 1E, right), thus
excluding the possibility that the difference was due to different
levels of protein expression and/or degradation. Of note, the TA
mutant was capable of IGF binding, although the binding appeared
to be somewhat reduced (Fig. 1C).
Radulescu (Radulescu, 1995) recognized that several basic
residues in the human IGFBP3 C-domain resembled a bipartite
nuclear localization signal (NLS). Schedlich and co-workers
(Schedlich et al., 1998) provided experimental evidence showing
that mutation of 228-KGRKR-232 into MDGEA abolished the
nuclear transport of human IGFBP3. This bipartite NLS is well
conserved in zebrafish Igfbp3 (Fig. 2A). When cells were transfected
with zebrafish Igfbp3–EGFP, the signal was seen exclusively in the
nucleus, often as a number of dots or speckles within the nucleus
(Fig. 2B). In comparison, the zebrafish Igfbp1a–EGFP signal was
only detected in the cytoplasm (Fig. 2B). We next engineered a NLS
mutant by changing four basic residues (236-KGRK-239) in the
NLS of zebrafish Igfbp3 into the corresponding sequence of zebrafish
Igfbp1a, LDGQ (Maures and Duan, 2002) (Fig. 2A). This NLS
mutant showed no nuclear localization (Fig. 2B), but had normal
IGF binding (Fig. 1C). We also engineered and tested an IBD and
NLS double mutant (IBD+NLS). As shown in Fig. 1C and Fig. 2B,
the IBD+NLS double mutant had impaired IGF binding and nuclear
localization. The TA mutant, however, had normal nuclear
localization (Fig. 2B).
Zebrafish Igfbp3 exerts ligand-dependent and ligand-
independent effects in vivo
To determine the functional roles of its conserved IBD, TA and
NLS in vivo, capped mRNAs encoding zebrafish Igfbp3 and its
various mutants were introduced into zebrafish embryos by
microinjection. As shown in Fig. 3A, forced expression of Igfbp3
caused shortened tail or a loss of tail and truncated body plan.
Based on the severity of the phenotypes, we grouped them into
three categories: weak, medium and severe (Fig. 3A). As shown in
Fig. 3B, forced expression of Igfbp3 resulted in more than 40%
abnormal embryos, whereas control embryos injected with egfp
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Fig. 2. Subcellular localization of zebrafish Igfbp3 and its various
mutants. (A)Sequence alignment of the nuclear localization signal (NLS)
motif in human IGFBP3 and zebrafish Igfbp3 and the corresponding region of
zebrafish Igfbp1a. The conserved crucial residues are boxed. (B)U2OS cells
were transfected with zebrafish Igfbp3–EGFP (BP3), its IBD mutant, NLS
mutant, IBD+NLS double mutant (I+N), or TA mutant expression plasmid.
Zebrafish Igfbp1a-EGFP (BP1a) and pC2+EGFP were used as negative
controls. The EGFP signal was visualized (left panel) 24 hours after
transfection. Corresponding DAPI staining is shown in the middle column and











mRNA alone were indistinguishable from intact embryos. In the
group injected with mRNA encoding Igfbp3 with a mutated IBD
(i.e. the IBD mutant), only about 20% of the embryos showed
weak or medium phenotypes. The results in the IBD+NLS double
mutant group were very similar to those of the IBD group (Fig.
3B). The results of the NLS mutant and TA mutant group were
similar to those of the wild-type Igfbp3 group. As mentioned
above, tagging EGFP to zebrafish Igfbp3 reduced its IGF binding
ability (Fig. 1B). Taking advantage of this finding, we injected
mRNA encoding Igfbp3–EGFP into zebrafish embryos as an
independent way to examine the IGF-binding-independent action.
As shown in Fig. 3C, more than 40% of the embryos in this group
showed an abnormal phenotype, whereas all embryos in the control
EGFP group were normal (Fig. 3C).
To determine whether the observed phenotypes were due to
changes in the dorsal–ventral axis, we performed in situ
hybridization using a number of dorsal–ventral axis marker genes.
floating head (flh) expression marks the dorsal axial mesoderm at
the stages of shield and 60% epiboly (Miller-Bertoglio et al., 1997;
Talbot et al., 1995). even-skipped-1 (eve1) and ventral edema (ved)
(Joly et al., 1993; Shimizu et al., 2002) are expressed in the ventral
non-axial mesoderm. T-box 24 (tbx24) is expressed in the paraxial
mesoderm at the stage of 80% epiboly (Nikaido et al., 2002).
Expression of zebrafish Igfbp3 or its IBD mutant markedly
increased the expression domains of flh (Fig. 3Dc,d). By contrast,
the expression domains of eve1 and ved were reduced in embryos
injected with mRNA encoding Igfbp3 or its IBD mutant (Fig.
3Dg,h,k,l and k,l). Forced expression of Igfbp3 or its IBD mutant
also squeezed or pushed the tbx24 expression domains to the
lateral sides, probably as a result of expansion of the dorsal
organizer (Fig. 3Do,p,o,p). These findings suggest that Igfbp3
and its IBD have dorsalizing effects in zebrafish embryos.
Igfbp3 exerts its IGF-independent action by antagonizing
Bmp2 signaling in vivo
The dorsalization of embryos caused by Igfbp3 resemble the
phenotypes of swirl and somitabun, two zebrafish genetic mutant
lines caused by the loss of bmp2b and its signaling transducer
smad5, respectively (Hild et al., 1999; Kishimoto et al., 1997). We
postulated that Igfbp3 might exert its IGF-independent action by
affecting BMP signaling. To test this hypothesis, co-expression
experiments were performed. As reported (Kishimoto et al., 1997),
injection of bmp2b mRNA had ventralizing effects in zebrafish
embryos (Fig. 4Av1–v4). Co-injection of zebrafish igfbp3 mRNA
with bmp2b mRNA markedly reduced the ventralizing effect of
Bmp2b (Fig. 4A,B). IBD had similar antagonizing effects (Fig.
4A,B).
We next examined the interaction between Igfbp3 and Bmp2b
in the formation of the dorsal–ventral axis. As shown in Fig. 4C,
forced expression of Bmp2b markedly reduced the expression
domains of flh, a dorsal marker gene, and co-expression of either
zebrafish Igfbp3 or its IBD mutant abolished this Bmp2b-related
reduction in expression (Fig. 4Cc,d,g,h; and Fig. 4D). Forced
expression of Bmp2b markedly increased the expression domains
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Fig. 3. Igfbp3 exerts both IGF-dependent and IGF-independent actions in
zebrafish embryos. (A)Classification of phenotypes caused by forced
expression of zebrafish Igfbp3. 1- to 2-cell embryos were injected with
zebrafish igfbp3 mRNA and raised to 24 h.p.f. Lateral views are shown. Scale
bar: 0.5 mm. (B)EGFP, zebrafish Igfbp3, IBD mutant, NLS mutant, IBD+NLS
double mutant (I+N), or TA mutant mRNA was injected into 1- to 2-cell-stage
embryos. The embryos were raised to 24 h.p.f. and their phenotypes were
scored based on the categories shown in A. The percentage of embryos in each
category is shown. The results shown are from three independent injection
experiments and the total embryo number in each group is shown on the top.
(C)24 h.p.f. wild-type embryos (WT), or embryos injected with egfp mRNA
(EGFP) or zebrafish igfbp3-egfp mRNA (BP3-EGFP) were scored based on
the categories shown in A and the percentage of embryos in each category is
shown. (D)Wild-type embryos (WT) or embryos injected with mRNA
encoding EGFP (EGFP), zebrafish Igfbp3 (BP3) or IBD mutant (IBD) were
analyzed by whole-mount in situ hybridization using the indicated probes. The
frequency of embryos with the indicated expression patterns is shown in the
bottom left corner of each panel. Panels a–p are animal pole view with dorsal
to the right; panels i–l are lateral view with animal pore up and dorsal to the
right; m–p are dorsal view with animal pore up. Arrows indicate the width of
the expression domain. Asterisks indicate the edges of ved expression domain.
Panels a–l and i–l, embryos at 60% epiboly; m–p and m–p, 80% epiboly.











of eve1 mRNA (Fig. 4Cf and Fig. 4E). Co-expression of zebrafish
Igfbp3 or its IBD mutant with Bmp2b, restored the expression of
eve1 to control levels (Fig. 4Cg,h, Fig. 4E). Similar results were
obtained with ved mRNA (Fig. 4Cj–l,j–l; Fig. 4F). Forced
expression of Bmp2b also caused expression domains of tbx24 to
converge in the middle point as a result of the reduction of the
dorsal organizer size (Fig. 4Cn,n; Fig. 4G). Co-expression of
Bmp2b with Igfbp3 or its IBD mutant restored the tbx24 expression
domains to the wild type and EGFP control levels (Fig. 4Co,p,o,p;
Fig. 4G).
To provide further evidence that Igfbp3 antagonizes Bmp2
signaling in zebrafish embryos, we examined the effect of Igfbp3
on Bmp2b-induced tp63 gene expression using whole-mount in
situ hybridization and real-time quantitative RT-PCR (qRT-PCR).
tp63 is a direct transcriptional target of Bmp signaling in zebrafish
(Bakkers et al., 2002). Injection of bmp2b mRNA alone resulted in
a marked expansion in the tp63 mRNA expression domains (Fig.
5A,B). Injection of mRNA encoding the Igfbp3 IBD mutant,
however, caused a major reduction in tp63 mRNA expression
domains. Most embryos co-injected with mRNA encoding Bmp2b
and the IBD mutant had an expression pattern that was similar to
the egfp mRNA control embryos (Fig. 5A,B). The qRT-PCR results
are shown in Fig. 5C. Forced expression of Bmp2b resulted in a
highly significant tenfold increase in tp63 mRNA levels. Co-
expression of Igfbp3 or its IBD mutant significantly inhibited the
Bmp2b-induced increase in tp63 mRNA expression. Expression of
Igfbp3 alone resulted in a significant decrease in tp63 mRNA
levels (Fig. 5C). These results suggest that Igfbp3 antagonizes
Bmp2 signaling in vivo and that this action of Igfbp3 is largely
independent of IGF binding.
IGFBP3 binds BMP2 and inhibits signaling and also
upregulates chordin gene expression
Many BMP antagonists, such as Chordin, Noggin and Follistatin,
inhibit BMP signaling by direct binding to BMP ligand (Iemura et
al., 1998; Piccolo et al., 1996; Zimmerman et al., 1996). We carried
out western ligand blotting assays to test whether IGFBP3 can
interact with BMP2 physically. As shown in Fig. 6A, DIG-labeled
BMP2 bound Noggin, which is well-established to bind and
antagonize BMP. Likewise, DIG–BMP2 bound IGFBP3, albeit at
a higher concentration. In comparison, DIG–BMP2 did not bind to
IGFBP1 and IGFBP6, two closely related proteins, but DIG-labeled
IGF-1 or IGF-2 was able to bind all three IGFBPs, but not Noggin
(supplementary material Fig. S1). In the absence of zebrafish
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Fig. 4. Igfbp3 antagonizes Bmp2b
action in zebrafish embryos via an
IGF binding independent mechanism.
(A)Classification of phenotypes caused
by forced expression of zebrafish Bmp2b
with zebrafish Igfbp3. Lateral views of
24 h.p.f. embryos are shown with dorsal
up. Ventralized embryos are classified
into four levels as indicated in v1–v4.
Dorsalized embryos are classified into
two levels as shown in c1 and c2. Scale
bar: 0.5 mm. (B)embryos injected with
the indicated mRNAs were raised to 24
h.p.f. and their phenotypes were scored
based on the categories shown in A.
Percentage of embryos in each category
is shown. The results are from three
independent experiments and the total
embryo number is given on the top.
(C)Embryos injected with the indicated
mRNAs were analyzed by whole mount
in situ hybridization using the indicated
probes. Panels a–p are animal pole view
with dorsal to the right; panels i–l are
lateral view with animal pore up and
dorsal to the right; m–p are dorsal view
with animal pole up. Arrows indicate the
width of the expression domain; asterisks
indicate the edges of the ved mRNA
expression domain. Panels a–l and i–l,
embryos at 60% epiboly; m–p and 
m–p, 80% epiboly. Scale bar: 0.25 mm.
Percentage of embryos in each category
was calculated and shown in D (flh), E
(eve1), F (ved) and G (tbx24). The total












Bmp2b protein, we tested whether IGFBP3 can bind to zebrafish
Bmp4, which is structurally closely related to Bmp2. As shown in
Fig. 6B, DIG-labeled zebrafish Bmp4 also bound IGFBP3 and
Noggin, but not IGFBP1 and IGFBP6. These results suggest that
IGFBP3 can directly bind BMP2 and BMP4. The effect of this
binding on BMP2 signaling was determined by measuring BMP2-
induced phosphorylation of the Smad1, Smad5 and Smad8 complex
(Samd1/5/8) in cultured U2OS cells. BMP2 strongly induced Smad
phosphorylation in this in vitro model (Fig. 6C). Co-incubation
with IGFBP3 inhibited BMP2-induced Smad phosphorylation in a
dose-dependent manner, whereas IGFBP3 alone had little effect
(Fig. 6C,D). These results suggest that IGFBP3 can bind to and
inhibit BMP2 signaling.
It is known that the expression of the chordin gene, which
causes dorsalization, is under the negative regulation of Bmp2
(Zakin and De Robertis, 2010). If Igfbp3 indeed bound to and
inhibited Bmp2b signaling in vivo, overexpression of Igfbp3 should
remove this negative regulation and increase chordin expression in
vivo. To test this idea, we analyzed chordin mRNA expression in
embryos injected with igfbp3 mRNA and mRNA encoding the
IBD mutant. Many of these injected embryos had expanded the
chordin mRNA expression domains (Fig. 7A,B). Co-injection
experiments with bmp2b mRNA resulted in a marked reduction in
the chordin mRNA expression domain (Fig. 7C,D). This effect of
Bmp2b was alleviated by the co-injection of mRNA encoding
either Igfbp3 or its IBD mutant (Fig. 7C,D). In good agreement
with the in situ hybridization results, qRT-PCR analysis also showed
that forced expression of Igfbp3 significantly increased chordin
mRNA levels (Fig. 7E). By contrast, expression of Bmp2b resulted
in a highly significant decrease in chordin mRNA levels. Co-
expression of either Igfbp3 or its IBD mutant with Bmp2b reversed
the inhibitory effect of Bmp2b on chordin expression (Fig. 7E).
These results suggest that Igfbp3 inhibits Bmp2 signaling in vivo.
Chordin regulates dorsal development, and overexpression of
Chordin can dorsalize zebrafish embryos (Hammerschmidt et al.,
1996; Miller-Bertoglio et al., 1997; Piccolo et al., 1996). To test
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Fig. 5. Expression of zebrafish Igfbp3 abolishes Bmp2b-induced target
gene expression in zebrafish embryos. (A)Whole mount in situ analysis
results of tp63 mRNA expression in embryos injected with the indicated
mRNA. a–d, lateral views with animal pore up and dorsal to the right; a–d,
animal pole views with dorsal to the right. Asterisks indicate the edges of the
tp63 mRNA expression domain. Embryos are at 80% epiboly. Scale bar: 0.25
mm. (B)Percentage of embryos in each category. The total embryo number is
shown on the top. (C)qRT-PCR results. Embryos were injected with the
indicated mRNA and raised to the 60% epiboly stage. The tp63 mRNA levels
were measured by qRT-PCR and normalized to -actin mRNA. The data are
expressed as fold increase over the wild-type (WT) group. Values are
expressed as means ± s.d., n3. *P<0.01 vs WT and GFP group; #P<0.01 vs
the Bmp2b group.
Fig. 6. IGFBP3 binds to BMP2 and inhibits BMP2-induced Smad
phosphorylation. (A)Ligand-blotting analysis of purified IGFBP1 (BP1),
IGFBP3 (BP3), IGFBP6 (BP6) and Noggin (Nog) proteins using DIG-labeled
BMP2 as ligand. Similar results were obtained from four experiments.
(B)Ligand-blotting analysis using DIG-labeled zebrafish Bmp4 as ligand.
Similar results were obtained from three other experiments. (C)IGFBP3
inhibits BMP2 signaling in vitro. 0.05g/ml BMP2 premixed with or without
0.5g/ml IGFBP3 was added to cultured U2OS cells. 3 hours later, cells were
lyzed and subjected to western immunoblotting analysis using antibodies
against total or phosphorylated Smad1/5/8. A representative gel is shown.
(D)Dose-dependent effect of IGFBP3 in inhibiting BMP2 signaling. Values
are expressed as means ± s.d., n3. Groups with different letters are











whether Igfbp3 and Chordin act additively or synergistically in
inhibiting Bmp2 signaling, we co-injected chordin mRNA and
igfbp3 mRNA into zebrafish embryos. Igfbp3 and Chordin had
additive dorsalizing effects in zebrafish embryos (Fig. 8A). To
investigate the physiological role of Igfbp3 and its relationship
with Chordin, we performed experiments to knock down Igfbp3
and Chordin individually and in combination, using validated
morpholino-modified oligonucleotides (MOs). Knockdown of
Igfbp3 alone caused defective pharyngeal arches, but it did not
alter dorsal–ventral patterning (Fig. 8B,C, WT-like phenotype).
Injection of Chordin MO alone resulted in a modest degree of
ventralization in over 90% of the embryos (Fig. 8B,C). Embryos
co-injected with chordin MO and igfbp3 MO showed a more
severe ventralized phenotype, with greatly reduced head, expanded
hematopoietic tissues and an enlarged tail (Fig. 8B,C;
supplementary material Fig. S2). These new results indicate that
Igfbp3 acts in a redundant manner with Chordin to antagonize
Bmp2 action in zebrafish embryos.
The BMP-antagonist action of IGFBP3 is evolutionarily
conserved
To determine whether the BMP-antagonizing action is conserved,
we injected mRNA encoding human IGFBP3 and its IBD mutant
into zebrafish embryos. Similarly to the use of zebrafish Igfbp3,
forced expression of human IGFBP3 or its IBD mutant resulted
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Fig. 7. Igfbp3 upregulates chordin gene expression by alleviating the
negative regulation of Bmp2. Whole-mount in situ analysis results of chordin
mRNA expression in wild-type embryos or embryos injected with the
indicated mRNA at shield stage (A) or 60% epiboly (C). Animal pole views
are shown with dorsal to the right. Arrows indicate the width of expression
domains. Scale bar: 0.25 mm. (B,D)Percentage of embryos in each category
shown in A or C, respectively. Total embryo number is on the top. (E)qRT-
PCR analysis results. chordin mRNA levels of the indicated group were
measured by qRT-PCR and normalized by -actin mRNA level. The results are
expressed as fold increase over the wild-type (WT) group. Values shown are
means ± s.d., n3. *P<0.05 and **P<0.01 vs WT and GFP group; #P<0.01 vs
the Bmp2b group.
Fig. 8. Igfbp3 acts in concert with Chordin to antagonize Bmp2 actions in
zebrafish embryos. (A)Igfbp3 and Chordin have additive dorsalizing effects.
Zebrafish embryos were injected with the indicated mRNA, raised to 24 h.p.f.,
and analyzed according to the phenotype categories shown in Fig. 3A. The
results shown are from three independent experiments with the total embryo
number shown on the top. (B,C)Igfbp3 functions redundantly to Chordin in
antagonizing Bmp action. 1- to 2-cell-stage zebrafish embryos were injected
with the indicated MOs, raised to 24 h.p.f., and analyzed according to the
phenotype categories shown in B. The frequency of each group was shown in
C, which was tabulated from three independent experiments with the total











in dorsalized zebrafish embryos in approximately 80% and 70%
of the injected embryos, respectively (Fig. 9A). To further address
this issue, we examined the effect of IGFBP3 on BMP2-induced
differentiation of mouse 10T1/2 cells. As reported by Katagiri
and colleagues (Katagiri et al., 1990), when human BMP2 was
added to cultured 10T1/2 cells, it caused a significant eightfold
increase in ALP activity (Fig. 9B). Addition of human IGFBP3
inhibited the BMP2-induced increase in ALP activity in a
concentration-dependent manner (Fig. 9B). These findings suggest
that the BMP2-antagonizing action of IGFBP3 is evolutionarily
conserved.
Discussion
In this study, we show that Igfbp3 acts in both IGF-binding-
dependent and -independent manners in zebrafish embryos and the
IBD, NLS and TA domains are all conserved and functional in
zebrafish Igfbp3. Taking advantage of the zebrafish model, we
examined the in vivo roles of these domains using a transgenic
approach. The results suggest that the IGF-independent action of
zebrafish Igfbp3 is not related to its nuclear localization or
transactivation activity. Our genetic and biochemical experiments
reveal that Igfbp3 exerts its IGF-independent actions by inhibiting
Bmp2 signaling, and this mechanism is evolutionarily conserved.
In a previous study, we showed that targeted knockdown of the
zebrafish igfbp3 gene resulted in defects in the development of
pharyngeal cartilage and the inner ear (Li et al., 2005). These
actions of Igfbp3 are probably IGF-dependent because targeted
knockdown or dominant-negative inhibition of the IGF-1 receptor
also resulted in defects in pharyngeal cartilage and the inner ear
(Li et al., 2005; Schlueter et al., 2007). In this study, we provide
further evidence supporting the notion that zebrafish Igfbp3 has
IGF-dependent actions. Our results showed that zebrafish Igfbp3
can bind to IGF ligands through its conserved IBD. When expressed
in zebrafish embryos, the activities of the two mutants with impaired
IGF binding ability (IBD mutant and IBD+NLS double mutant)
were lower compared with that of the wild-type protein. Our in
vivo experiments also demonstrated the IGF-independent action of
Igfbp3 in zebrafish embryos. This is supported by the fact that the
IBD mutant, which had little IGF binding activity, had significant
dorsalizing activity in zebrafish embryos. Another line of evidence
is that Igfbp3–EGFP, which had impaired IGF binding, had strong
dorsalizing activity.
Mammalian IGFBP3 has been shown to possess distinct
biological effects independently of IGF and IGF-1R (Firth and
Baxter, 2002; Jogie-Brahim et al., 2009). There are several
competing models regarding the molecular mechanisms
underlying these IGF-independent actions of IGFBP3, including
(1) interaction of IGFBP3 with its putative cell surface receptor;
(2) nuclear localization and nuclear actions; (3) intracellular (but
non-nuclear) action. Studies from a number of labs have shown
that IGFBP3 has a functional NLS in its C-domain and is capable
of nuclear translocation in cultured human tumor cells, and it can
interact with retinoid-X receptor-a and other nuclear proteins in
the nucleus (Liu et al., 2000; Oufattole et al., 2006). In addition,
the N-domain of mammalian IGFBP3 has been shown to possess
intrinsic transactivation activity (Zhao et al., 2006). Despite these
findings, the in vivo significance of the nuclear localization and
transactivation activity of IGFBP3 has not been explored. Our
results show that the NLS mutant, which had impaired nuclear
localization, and the transcription-dead TA mutant exhibited
similar activity in dorsalizing the embryo to that seen with intact
Igfbp3. These findings suggest that the dorsalizing effect of
Igfbp3 is not dependent on its nuclear localization or
transactivation activity in zebrafish embryos. These in vivo results
in zebrafish are consistent with recent in vitro studies in human
breast and prostate cancer cells, which show that the ability of
IGFBP3 to inhibit cell growth and cause apoptosis does not
require its nuclear localization (Butt et al., 2002). A more recent
study reported that induction of apoptosis in human prostate
cancer cells by IGFBP3 does not require binding to retinoid-X
receptor-a either (Zappala et al., 2008). Taken together, these
findings indicate that at least some of the ligand-independent
actions of IGFBP3 are not related to its nuclear localization or
transactivation activity. However, the high degree of structural
and functional conservation of the NLS and TA uncovered by the
current study, as well as previous reports on the functional
interactions between nuclear IGFBP3 and several transcription
factors suggest that these domains are functional. The nuclear
actions of IGFBP3 might be dependent on the tissue,
developmental stage and/or pathophysiological state.
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Fig. 9. The BMP-antagonizing action of IGFBP3 is
evolutionarily conserved. (A)1- to 2-cell-stage embryos were
injected with mRNA encoding human IGFBP3 (BP3) or its IBD
mutant (IBD). The injected embryos were raised to 24 h.p.f. and
analyzed according to the phenotype categories shown in Fig. 3A.
The results shown are from three independent experiments with the
total embryo number shown on the top. (B)Human IGFBP3 inhibits
BMP2-induced cell differentiation. 10T1/2 cells were treated with
or without human IGFBP3 (BP3). 48 hours later, cells were
changed into serum-containing medium supplemented with human
BMP2 (1g/ml). Four days later, cells were harvested and
subjected to ALP activity assay. The ALP activity was normalized
by total protein levels and expressed as fold over the control. Values
are means ± s.d., n6. Groups with different letters are significantly
different from each other (P<0.05). (C)A proposed model on the
involvement of Igfbp3 in the Bmp signaling pathway in zebrafish
embryos. Igfbp3 binds to Bmp2–Bmp4 (Bmp2/4) and inhibits its
binding to its receptor and thereby Smad signaling. The reduced
Bmp2/4 signaling leads to an increase in chordin gene expression as
a result of alleviation of the negative regulation of Bmp2/4. The
increased Chordin acts together with Igfbp3 to further antagonize











A novel finding made in this study is that Igfbp3 exerts its
ligand-binding-independent actions by antagonizing Bmp2
signaling (Fig. 9C). The Bmp signaling pathway has a crucial role
in controlling the dorsal–ventral patterning in the zebrafish embryo
(Schier and Talbot, 2005). Bmp signaling also regulates non-axial
mesoderm patterning during gastrulation (Ramel et al., 2005) and
is required for tail development in zebrafish (Agathon et al., 2003).
As mentioned earlier, swirl and somitabun, two zebrafish genetic
mutant lines caused by loss of function of bmp2b or smad5,
exhibited the dorsalized phenotypes (Hild et al., 1999; Kishimoto
et al., 1997). Forced expression of bmp2b in zebrafish embryos
resulted in ventralized phenotypes (Kishimoto et al., 1997). In this
study, we show that Igfbp3 antagonizes this action of Bmp2b.
When co-expressed with Bmp2b in zebrafish embryos, Igfbp3
reduced Bmp2b-induced ventralization and abolished Bmp2b-
induced tp63 gene expression. Additionally, forced expression of
Igfbp3 alone resulted in the dorsalized phenotypes, probably by
blocking endogenous Bmp2 signaling. Importantly, the IBD mutant
had similar effects. These results strongly suggest that zebrafish
Igfbp3 can antagonize Bmp2 signaling in vivo, and this action is
independent of IGF binding.
Many BMP antagonists, such as Chordin, Noggin and Follistatin,
inhibit BMP signaling by forming a complex with a BMP ligand
(Iemura et al., 1998; Piccolo et al., 1996; Zimmerman et al., 1996).
Our biochemical data revealed that human IGFBP3 can also form a
physical complex with BMP2. This interaction is specific to IGFBP3
because BMP2 did not bind to IGFBP1 or IGFBP6. Importantly,
binding of IGFBP3 to BMP2 has functional significance because it
inhibited BMP2-induced phosphorylation of Smad1/5/8 when tested
in cultured human cells. In developing zebrafish embryos, igfbp3
mRNA was first detected in the migrating neural crest cells and
subsequently concentrated in pharyngeal arches and the inner ears
(Li et al., 2005). bmp2b is widely expressed in early embryos, and
becomes progressively restricted to the ventral half of the embryo
by the onset of gastrulation (Kishimoto et al., 1997) and then
expressed in otic vesicles (Martinez-Barbera et al., 1997) and
pharyngeal endoderm (Thisse et al., 2004). Therefore, these two
genes share overlapping domains, at least at some stage during
embryogenesis. Moreover, both Bmp2 and Igfbp3 are secreted
proteins and they can diffuse to surrounding tissues. Therefore, it is
possible that they interact with each other in vivo.
Another interesting finding is that the expression of chordin, a
well-known Bmp antagonist (Piccolo et al., 1996) that regulates
dorsal development in zebrafish (Hammerschmidt et al., 1996),
was upregulated in embryos injected with igfbp3 mRNA. Because
Bmp2 negatively regulates chordin gene expression at the
transcriptional level (Zakin and De Robertis, 2010), the elevated
chordin mRNA expression in Igfbp3-injected embryos is probably
due to the binding and inhibition of Bmp2 signaling by zebrafish
Igfbp3. Indeed, the results of co-injection experiments indicated
that Bmp2b expression inhibited chordin gene expression in
zebrafish embryos, and this action was attenuated by the co-
expression of zebrafish Igfbp3. This action is independent of IGF
because the IBD mutant had a similar effect. Further knockdown
experiments indicate that Igfbp3 acts in a redundant manner to
Chordin to antagonize Bmp2 in zebrafish embryos. Embryos
injected with chordin MO and igfbp3 MO showed more severe
phenotypes with a greatly reduced head, expanded hematopoietic
tissues and an enlarged tail compared with those injected with
Chordin MO alone. A similar redundant relationship with Chordin
has been reported for another BMP antagonist, Noggin, in zebrafish
(Dal-Pra et al., 2006). This conclusion is further supported by
overexpression studies, showing that Igfbp3 and Chordin had
additive effects in antagonizing Bmp2. These results have led to a
mechanistic model explaining the IGF-independent action of Igfbp3
in zebrafish embryos (Fig. 9C). According to the model, Igfbp3
binds to Bmp2 and possibly Bmp4 and inhibits its binding to its
receptor and downstream Smad signaling activity. The reduced
Bmp2 signaling leads to an increase in chordin gene expression as
a result of the alleviation of the negative regulation of chordin
gene expression by Bmp2. The increased Chordin in turn acts
together with Igfbp3 to further antagonize Bmp2 activity. This
results in the dorsalization of embryos.
The action of IGFBP3 in antagonizing BMP signaling appears
to be evolutionarily conserved. This is supported by several lines
of evidence: (1) human IGFBP3 and its IBD mutant had similar
dorsalizing effects when expressed in zebrafish embryos; (2) human
IGFBP3 inhibited human BMP2-induced Smad phosphorylation in
cultured human U2OS cells in a dose-dependent manner; and (3)
human IGFBP3 inhibited BMP2 action in 10T1/2 cell
differentiation. BMPs belong to the TGF superfamily. Recent
studies in a variety of mammalian cell cultures systems show that
IGFBP3 can regulate cell growth and apoptosis by interacting with
TGF at multiple levels (Fanayan et al., 2002; Fanayan et al.,
2000; Forbes et al., 2010; Kuemmerle et al., 2004; Peters et al.,
2006). In T47D breast cancer cells, the anti-growth action of
IGFBP3 requires TGF receptor I/II and the downstream Smad2/3
(Fanayan et al., 2002; Fanayan et al., 2000). In human
cytotrophoblasts, IGFBP3 was shown to affect basal proliferation
via TGF receptor I/II and Smad2 (Forbes et al., 2010). Kuemmerle
and co-workers (Kuemmerle et al., 2004) showed a direct binding
of IGFBP3 to TGF receptor type II and V. A recent study
(Mukherjee and Rotwein, 2008) reported that IGFBP5, the most
closely related member of the IGFBP family, inhibited BMP-
induced cell differentiation in an IGF-dependent manner. Although
our data suggest that IGFBP3 can antagonize BMP signaling by
binding to BMP2, other mechanisms might also be involved in the
BMP-antagonizing action of IGFBP3.
Regulation of peptide growth factor by secreted binding proteins
has emerged as a common theme in cell-to-cell signaling. Among
the most extensively studied examples is IGFBP3. This
multifunctional protein is involved in the regulation of cell
proliferation, growth, migration, differentiation and apoptosis. The
results of this study reveal that IGFBP3 acts in an IGF-dependent
as well as an IGF-independent manner in a vertebrate animal
model. Moreover, we discovered that IGFBP3 exerts IGF-
independent actions by binding to and antagonizing BMP2
signaling. The results of this study provide new insights on the
structural and functional conservation of the IGF binding, nuclear
localization and transactivation domains of this multifunctional
IGFBP. A better understanding of the molecular basis underlying
the action of IGFBP3 will not only further our knowledge of
IGFBP physiology but might also lead to future strategies for
treating or circumventing human diseases.
Materials and Methods
Materials
Chemicals and reagents were purchased from Fisher Scientific (Pittsburgh, PA)
unless noted otherwise. IGFs were purchased from GroPep (Adelaide, Australia) and
IGFBPs and BMPs from R&D systems (Minneapolis, MN). Human Noggin was
purchased from Neuromics (Edina, MN). Digoxigenin and anti-digoxigenin-POD
antibody were purchased from Roche (Indianapolis, IN). Anti-GFP antibody was
purchased from Torrey Pines Biolabs (East Orange, NJ). The anti- phosphorylated
Smad1/5/8 antibody was purchased from Cell Signaling Technology (Danvers, MA)











and the total Smad1/5/8 antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). RNA polymerase and RNase-free DNase were purchased from
Promega (Madison, WI). Taq DNA polymerase and endonucleases were purchased
from New England BioLabs (Beverly, MA). PfuUltraTM II Fusion DNA Polymerase
and STRATAClEANTM Resin were purchased from Stratagene (LA Jolla, CA). M-
MLV reverse transcriptase and oligonucleotide primers were purchased from
Invitrogen Life Technologies (Carlsbad, CA).
Experimental animals
Wild-type zebrafish (Danio rerio) were maintained on a 14 hour light, 10 hour dark
cycle and fed twice daily. Embryos were obtained by natural cross. Fertilized eggs
were raised at 28.5°C and staged according to Kimmel and colleagues (Kimmel et
al., 1995). 2-phenylthiourea [0.003% (w/v)] was added to the embryo rearing solution
in some experiments to inhibit embryo pigment formation. All experiments were
conducted in accordance with guidelines approved by the University Committee on
the Use and Care of Animals at the University of Michigan.
Plasmid construction
The construction of the pCS2+Igfbp3 plasmid was reported (Li et al., 2005). The
zebrafish Igfbp3 mutants were generated by site-directed mutagenesis using
PfuUltraTM II Fusion DNA Polymerase. For the IBD mutant, K70, P71, L72, L75
and L76 were mutated to N, Q, Q, Q and Q. The NLS mutant was generated by
mutating 236-KGRK-239 into LDGQ, the corresponding sequence of zebrafish
Igfbp1a. The IBD+NLS double mutant was generated using the IBD mutant DNA
as the template. The TA dead mutant was generated by changing E8, D11, D12 and
E44 in zebrafish Igfbp3 into the corresponding residues of human IGFBP1. For
cellular localization studies, DNA encoding Igfbp3 and its mutants were subcloned
to the pCS2+EGFP vector. For this, the sense primer contains a BamHI site 
followed by Kozak and the start of coding sequence: 5-
CGGGATCCGCCACCATGACAGGTCTGTGTGCGCTC-3. The antisense primer
contained an EcoRI site followed by the last seven amino acid coding sequence of
zebrafish Igfbp3 without its stop codon: 5-CGGAATTCGCTTTGTCTCCATG -
TTATAGC-3.
To generate Gal4DNA binding domain (DBD) and Igfbp3 fusion protein constructs,
DNA fragments encoding zebrafish Igfbp3 N-domain or its TA mutant were amplified
by PCR. The PCR products were cloned into the BamHI-NotI sites of the pBind
vector to fuse the Igfbp3 in-frame to the C-terminus of Gal4DBD.
Zebrafish bmp2b (GenBank: NM 131360) cDNA was cloned into the pCS2+
vector using the BamHI and EcoRI sites. Human IGFBP3 and its IBD mutant were
generated as previously reported (Imai et al., 2000). tp63 (NM_152248) partial
sequence used for the whole mount in situ hybridization was amplified. This sequence
was subcloned into pGEM-T easy (Promega). Probe for tp63 was linearized with
NdeI and synthesized with T7.
Cell culture, transfection, and one-hybrid transcription activation assay
Human embryonic kidney (HEK) 293T cells, U2 osteosarcoma (U2OS) cells, and
mouse C3H/10T1/2 clone 8 cells, purchased from American Type Culture Collection
(Manassas, VA), were cultured according to ACTT’s recommendation. To produce
Igfbp3 and its mutant proteins, 2 g pCS2+Igfbp3 and its mutant DNA were
transfected into HEK293 cells, respectively. Conditioned media were prepared as
reported previously (Duan et al., 1999). For one-hybrid assay, 500 ng pBind or
pBind-IGFBP DNA and 500 ng pG5-luc DNA were co-transfected into cells as
reported previously (Xu et al., 2004). 24 hours after transfection, cells were washed
with PBS and lyzed in lysis buffer. Protein concentration was determined using a
BCA protein assay kit (Pierce). Transcription activation was quantified using the
Dual-Luciferase Reporter assay system (Promega). Firefly luciferase activity was
divided by Renilla luciferase activity to normalize for transfection efficiency.
Western immunoblotting and ligand blotting and subcellular localization
Cell lysates or conditioned media from transfected cells were subjected to western
blotting. IGFs, and BMPs were labeled with digoxingenin and used in ligand blotting
following published methods (Shimizu et al., 2000). Subcellular localization studies
were performed following published procedure (Xu et al., 2004).
Microinjection experiment
Capped mRNA synthesis was carried out using a commercial kit and linearized
plasmid DNA as a template (mMESSAGE mMACHINE kit; Ambion). 1 nl Igfbp3
or its mutant mRNA was microinjected into 1- to 2-cell-stage zebrafish embryos (1
ng/embryo). For co-injection experiment, bmp2b mRNA (2.5 pg/embryo) was injected
with or without igfbp3 mRNA or mRNA encoding Igfbp3 with mutant IBD (1
ng/embryo); chordin mRNA (20 pg/embryos) was injected with or without igfbp3
mRNA (500 pg/embryos). Embryos injected with egfp mRNA and intact embryos
were used as controls. Previously validated morpholino-modified oligonucleotides
(MOs) were used to knock down Igfbp3 (Li et al., 2005) and/or Chordin (Nasevicius
and Ekker, 2000). The MO were dissolved in 1 Danieau Solution and injected into
1- to 2-cell-stage embryos, as reported previously (Li et al., 2005). A standard
control MO was used as the control (Gene Tools, LLC, Philomath, OR). Embryos
were injected with 4 ng control MO, 2 ng control MO plus 2 ng chordin MO, 2 ng
chordin MO plus 2 ng igfbp3 MO, or 2 ng control MO plus igfbp3 MO, respectively.
After microinjection, embryos were raised in embryo-rearing medium (Westerfield,
1995) and kept at 28.5°C. Live embryos were imaged.
Whole-mount in situ hybridization and qRT-PCR analysis
Whole-mount in situ hybridization was performed as reported previously (Maures
and Duan, 2002). For qRT-PCR analysis, total RNA was extracted using TRIzol
Reagent according to the manufacturer’s instruction (Invitrogen Life Technologies,
Carlsbad, CA). After DNase treatment, RNA (1 g) was reverse-transcribed with
random hexamer primers and M-MLV reverse transcriptase. qPCR was carried out
in an iCycler iQ Multicolor real-time PCR detection system (Bio-Rad Laboratories,
Hercules, CA) using SYBR® Premix Ex TaqTM (Takara Bio, Liaoning, China).
Sequences of primers used for qPCR were: tp63 (forward, 5-AGAGAT -
GGTCAGGTTTTGGG-3; reverse, 5-GTGCTGTTTGCGGATGC-3); chordin
(forward, 5-ACGCCTGCTGCCATACAAT-3; reverse, 5-CACTGAGGGT -
CCACCGAGA-3); and -actin (forward, 5-AGAGTCCATCACGATACCAG-3;
reverse, 5-AGAGTCCATCACGATACCAG-3). Each sample was measured in
duplicate. tp63 and chordin mRNA levels were calculated using 2–Ct method
(Livak and Schmittgen, 2001) and presented as relative (fold) values of the control
group after values were normalized to levels of -actin.
In vitro BMP2 signaling activity
Human U2OS cells were seeded into 24-well plates. After 24 hours, the cells were
washed and serum starved for 3 hours. 50 ng/ml human BMP2 were premixed and
incubated with or without human IGFBP3 at various concentrations for 3 hours at
room temperature. The premixed solution was added to the U2OS cells. 3 hours
later, cells were harvested in RIPA buffer containing protease and phosphatase
inhibitors (10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM PMSF,
1 mM sodium orthovanadate, 1 mM sodium fluoride) and subjected to western
immunoblotting.
Alkaline phosphatase (ALP) activity assay
The effects of human IGFBP3 and BMP2 on cell differentiation were examined in
C3H/10T1/2 cells following the published method (Katagiri et al., 1990). ALP
activity was measured using an Alkaline Phosphatase Assay kit (AnaSpec).
Statistical analysis
Values are presented as means ± s.d. Differences among groups were analyzed by
one-way ANOVA followed by Tukey’s Multiple Comparison Test or by unpaired t
test using GraphPad Prism version 5.01 (San Diego, CA). Significance was accepted
at P<0.05.
We thank Lisa Hebda and Catherine Nosal and John Allard,
University of Michigan for proof reading this manuscript. We are
grateful for A. C. Lekven, W. S. Talbot and H. Condamine for providing
reagents. This study was supported by NSF Research Grant IOB
0110864, and Natural Scientific Foundation of China Grant 30928021,
and the University Innovation Project Seed Grant 070742 from the
Chinese Ministry of Education. Y.Z. is supported in part by a fellowship
from China Scholarship Council.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/124/11/1925/DC1
References
Agathon, A., Thisse, C. and Thisse, B. (2003). The molecular nature of the zebrafish tail
organizer. Nature 424, 448-452.
Bakkers, J., Hild, M., Kramer, C., Furutani-Seiki, M. and Hammerschmidt, M.
(2002). Zebrafish DeltaNp63 is a direct target of Bmp signaling and encodes a
transcriptional repressor blocking neural specification in the ventral ectoderm. Dev. Cell
2, 617-627.
Buckway, C. K., Wilson, E. M., Ahlsen, M., Bang, P., Oh, Y. and Rosenfeld, R. G.
(2001). Mutation of three critical amino acids of the N-terminal domain of IGF-binding
protein-3 essential for high affinity IGF binding. J. Clin. Endocrinol. Metab. 86, 4943-
4950.
Butt, A. J., Fraley, K. A., Firth, S. M. and Baxter, R. C. (2002). IGF-binding protein-
3-induced growth inhibition and apoptosis do not require cell surface binding and
nuclear translocation in human breast cancer cells. Endocrinology 143, 2693-2699.
Clemmons, D. R. (2007). Modifying IGF1 activity: an approach to treat endocrine
disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 6, 821-833.
Dal-Pra, S., Furthauer, M., Van-Celst, J., Thisse, B. and Thisse, C. (2006). Noggin1
and Follistatin-like2 function redundantly to Chordin to antagonize BMP activity. Dev.
Biol. 298, 514-526.
Duan, C. and Xu, Q. (2005). Roles of insulin-like growth factor (IGF) binding proteins
in regulating IGF actions. Gen. Comp. Endocrinol. 142, 44-52.
Duan, C., Ding, J., Li, Q., Tsai, W. and Pozios, K. (1999). Insulin-like growth factor
binding protein 2 is a growth inhibitory protein conserved in zebrafish. Proc. Natl.
Acad. Sci. USA 96, 15274-15279.
Fanayan, S., Firth, S. M., Butt, A. J. and Baxter, R. C. (2000). Growth inhibition by
insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires











transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J. Biol.
Chem. 275, 39146-39151.
Fanayan, S., Firth, S. M. and Baxter, R. C. (2002). Signaling through the Smad pathway
by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to
transforming growth factor-beta 1 signaling. J. Biol. Chem. 277, 7255-7261.
Firth, S. M. and Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor
binding proteins. Endocr. Rev. 23, 824-854.
Forbes, K., Souquet, B., Garside, R., Aplin, J. D. and Westwood, M. (2010).
Transforming growth factor-{beta} (TGF{beta}) receptors I/II differentially regulate
TGF{beta}1 and IGF-binding protein-3 mitogenic effects in the human placenta.
Endocrinology 151, 1723-1731.
Hammerschmidt, M., Pelegri, F., Mullins, M. C., Kane, D. A., van Eeden, F. J.,
Granato, M., Brand, M., Furutani-Seiki, M., Haffter, P., Heisenberg, C. P. et al.
(1996). dino and mercedes, two genes regulating dorsal development in the zebrafish
embryo. Development 123, 95-102.
Hild, M., Dick, A., Rauch, G. J., Meier, A., Bouwmeester, T., Haffter, P. and
Hammerschmidt, M. (1999). The smad5 mutation somitabun blocks Bmp2b signaling
during early dorsoventral patterning of the zebrafish embryo. Development 126, 2149-
2159.
Hong, J., Zhang, G., Dong, F. and Rechler, M. M. (2002). Insulin-like growth factor
(IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in
human prostate cancer cells. J. Biol. Chem. 277, 10489-10497.
Iemura, S., Yamamoto, T. S., Takagi, C., Uchiyama, H., Natsume, T., Shimasaki, S.,
Sugino, H. and Ueno, N. (1998). Direct binding of follistatin to a complex of bone-
morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early
Xenopus embryo. Proc. Natl. Acad. Sci. USA 95, 9337-9342.
Imai, Y., Moralez, A., Andag, U., Clarke, J. B., Busby, W. H., Jr and Clemmons, D.
R. (2000). Substitutions for hydrophobic amino acids in the N-terminal domains of
IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol.
Chem. 275, 18188-18194.
Jogie-Brahim, S., Feldman, D. and Oh, Y. (2009). Unraveling insulin-like growth factor
binding protein-3 actions in human disease. Endocr. Rev. 30, 417-437.
Joly, J. S., Joly, C., Schulte-Merker, S., Boulekbache, H. and Condamine, H. (1993).
The ventral and posterior expression of the zebrafish homeobox gene eve1 is perturbed
in dorsalized and mutant embryos. Development 119, 1261-1275.
Katagiri, T., Yamaguchi, A., Ikeda, T., Yoshiki, S., Wozney, J. M., Rosen, V., Wang,
E. A., Tanaka, H., Omura, S. and Suda, T. (1990). The non-osteogenic mouse
pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by
recombinant human bone morphogenetic protein-2. Biochem. Biophys. Res. Commun.
172, 295-299.
Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. and Schilling, T. F. (1995).
Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253-310.
Kishimoto, Y., Lee, K. H., Zon, L., Hammerschmidt, M. and Schulte-Merker, S.
(1997). The molecular nature of zebrafish swirl: BMP2 function is essential during
early dorsoventral patterning. Development 124, 4457-4466.
Kuemmerle, J. F., Murthy, K. S. and Bowers, J. G. (2004). IGFBP-3 activates TGF-
beta receptors and directly inhibits growth in human intestinal smooth muscle cells. Am.
J. Physiol. Gastrointest. Liver Physiol. 287, G795-G802.
Li, Y., Xiang, J. and Duan, C. (2005). Insulin-like growth factor-binding protein-3 plays
an important role in regulating pharyngeal skeleton and inner ear formation and
differentiation. J. Biol. Chem. 280, 3613-3620.
Liu, B., Lee, H. Y., Weinzimer, S. A., Powell, D. R., Clifford, J. L., Kurie, J. M. and
Cohen, P. (2000). Direct functional interactions between insulin-like growth factor-
binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and
apoptosis. J. Biol. Chem. 275, 33607-33613.
Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25,
402-408.
Martinez-Barbera, J. P., Toresson, H., Da Rocha, S. and Krauss, S. (1997). Cloning
and expression of three members of the zebrafish Bmp family: Bmp2a, Bmp2b and
Bmp4. Gene 198, 53-59.
Maures, T. J. and Duan, C. (2002). Structure, developmental expression, and physiological
regulation of zebrafish IGF binding protein-1. Endocrinology 143, 2722-2731.
Miller-Bertoglio, V. E., Fisher, S., Sanchez, A., Mullins, M. C. and Halpern, M. E.
(1997). Differential regulation of chordin expression domains in mutant zebrafish. Dev.
Biol. 192, 537-550.
Mukherjee, A. and Rotwein, P. (2008). Insulin-like growth factor-binding protein-5
inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth
factor actions. Mol. Endocrinol. 22, 1238-1250.
Nasevicius, A. and Ekker, S. C. (2000). Effective targeted gene ‘knockdown’ in zebrafish.
Nat. Genet. 26, 216-220.
Nikaido, M., Kawakami, A., Sawada, A., Furutani-Seiki, M., Takeda, H. and Araki,
K. (2002). Tbx24, encoding a T-box protein, is mutated in the zebrafish somite-
segmentation mutant fused somites. Nat. Genet. 31, 195-199.
Oufattole, M., Lin, S. W., Liu, B., Mascarenhas, D., Cohen, P. and Rodgers, B. D.
(2006). Ribonucleic acid polymerase II binding subunit 3 (Rpb3), a potential nuclear
target of insulin-like growth factor binding protein-3. Endocrinology 147, 2138-2146.
Peters, I., Tossidou, I., Achenbach, J., Woroniecki, R., Mengel, M., Park, J. K.,
Paschy, M., de Groot, K., Haller, H. and Schiffer, M. (2006). IGF-binding protein-3
modulates TGF-beta/BMP-signaling in glomerular podocytes. J. Am. Soc. Nephrol. 17,
1644-1656.
Piccolo, S., Sasai, Y., Lu, B. and De Robertis, E. M. (1996). Dorsoventral patterning in
Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 86,
589-598.
Radulescu, R. T. (1995). From insulin, retinoblastoma protein and the insulin receptor to
a new model on growth factor specificity: the nucleocrine pathway. J. Endocrinol. 146,
365-368.
Ramel, M. C., Buckles, G. R., Baker, K. D. and Lekven, A. C. (2005). WNT8 and
BMP2B co-regulate non-axial mesoderm patterning during zebrafish gastrulation. Dev.
Biol. 287, 237-248.
Schedlich, L. J., Young, T. F., Firth, S. M. and Baxter, R. C. (1998). Insulin-like growth
factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport
pathway in T47D human breast carcinoma cells. J. Biol. Chem. 273, 18347-18352.
Schier, A. F. and Talbot, W. S. (2005). Molecular genetics of axis formation in zebrafish.
Annu. Rev. Genet. 39, 561-613.
Schlueter, P. J., Peng, G., Westerfield, M. and Duan, C. (2007). Insulin-like growth
factor signaling regulates zebrafish embryonic growth and development by promoting
cell survival and cell cycle progression. Cell Death Differ. 14, 1095-1105.
Shimizu, M., Swanson, P., Fukada, H., Hara, A. and Dickhoff, W. W. (2000).
Comparison of extraction methods and assay validation for salmon insulin-like growth
factor-I using commercially available components. Gen. Comp. Endocrinol. 119, 26-36.
Shimizu, T., Yamanaka, Y., Nojima, H., Yabe, T., Hibi, M. and Hirano, T. (2002). A
novel repressor-type homeobox gene, ved, is involved in dharma/bozozok-mediated
dorsal organizer formation in zebrafish. Mech. Dev. 118, 125-138.
Talbot, W. S., Trevarrow, B., Halpern, M. E., Melby, A. E., Farr, G., Postlethwait, J.
H., Jowett, T., Kimmel, C. B. and Kimelman, D. (1995). A homeobox gene essential
for zebrafish notochord development. Nature 378, 150-157.
Thisse, B., Heyer, V., Lux, A., Alunni, V., Degrave, A., Seiliez, I., Kirchner, J., Parkhill,
J. P., and Thisse, C. (2004). Spatial and temporal expression of the zebrafish genome
by large-scale in situ hybridization screening. Methods Cell Biol. 77, 505-519.
Westerfield, M. (1995). The Zebrafish Book. Eugene, OR: University of Oregon Press.
Xu, Q., Li, S., Zhao, Y., Maures, T. J., Yin, P. and Duan, C. (2004). Evidence that IGF
binding protein-5 functions as a ligand-independent transcriptional regulator in vascular
smooth muscle cells. Circ. Res. 94, E46-E54.
Yamada, P. M. and Lee, K. W. (2009). Perspectives in mammalian IGFBP-3 biology:
local vs. systemic action. Am. J. Physiol. Cell Physiol. 296, C954-C976.
Zakin, L. and De Robertis, E. M. (2010). Extracellular regulation of BMP signaling.
Curr. Biol. 20, R89-R92.
Zappala, G., Elbi, C., Edwards, J., Gorenstein, J., Rechler, M. M. and Bhattacharyya,
N. (2008). Induction of apoptosis in human prostate cancer cells by insulin-like growth
factor binding protein-3 does not require binding to retinoid X receptor-alpha.
Endocrinology 149, 1802-1812.
Zhao, Y., Yin, P., Bach, L. A. and Duan, C. (2006). Several acidic amino acids in the N-
domain of insulin-like growth factor-binding protein-5 are important for its
transactivation activity. J. Biol. Chem. 281, 14184-14191.
Zimmerman, L. B., De Jesus-Escobar, J. M. and Harland, R. M. (1996). The Spemann
organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86,
599-606.
1935IGFBP3 is a BMP antagonist
Jo
ur
na
l o
f C
el
l S
ci
en
ce
